Economic cost of peripheral blood progenitor cell transplantation in Spain;Trasplante de progenitores hematopoyéticos de sangre periférica en España: Análisis de coste

Medicina Clinica

Volumn 123, Issue 11, 2004, Pages 401-405

  Sánchez Blanco, José Javier ^a   Lozano, María Luisa ^a,b   De Arriba, Felipe ^a   Vallejo, Carlos ^a   Vicente, Vicente ^a   Moraleda, José María ^a  

^a HOSPITAL MORALES MESEGUER   (Spain)

^b HOSPITAL UNIVERSITARIO MORALES MESEGUER   (Spain)

Author keywords

Cost; Hematopoietic progenitors; Transplantation

Indexed keywords

BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; MELPHALAN; THIOTEPA;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CELL ISOLATION; CRYOPRESERVATION; ECONOMIC EVALUATION; EVALUATION; FEMALE; HEALTH CARE COST; HISTOCOMPATIBILITY TEST; HOSPITALIZATION; HUMAN; INTERMETHOD COMPARISON; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MONEY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; SPAIN; WHOLE BODY RADIATION;

EID: 7944224936     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13066574     Document Type: Article

References (20)

1. Gatti RA, Meuwissen HJ, Allen HD, Hong R, Good RA. Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet 1968;2:1366-9.
2. Goldman JM, Horowitz MM. The international bone marrow transplant registry. Int J Hematol 2002;76(Suppl 1):393-7.
3. Welch G, Larson E. Cost-effectiveness of bone marrow transplantation in acute non-lymphocytic leukemia. N Engl J Med 1989;32:807-12.
4. Waters TM, Bennett CL, Pajeau TS, Sobocinsky KA, Klein JP, Rowlings P, et al. Economic analyses of bone marrow and blood stem cell transplantation for leukemias and lymphoma: what do we know? Bone Marrow Transplant 1998;21:641-50.
5. Smith TJ, Hillner BE, Schnitz N, Linch DC, Dreger P, Goldstone A, et al. Economic analysis of a randomized clinical trial to compare filgrastimmobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma. J Clin Oncol 1997;15:5-10.
6. Barosi G, Marchetti M, Alessandrino P, Locatelli F, Casula S, Lunghi M, et al. A model for analysing the cost of autologous peripheral blood progenitor cell (PBPC) transplantation. Bone Marrow Transplant 1999;23:719-25.
7. Juliá A, Bueno J, Gadea N, Massuet D, Del Baño C. Estudio económico del coste del autotrasplante de precursores hematopoyéticos de sangre periférica comparado con el de médula ósea. Med Clin (Barc) 1995;105:131-5.
8. De Arriba F, Heras I, García MC, Moraleda JM, Funes C, Ferrer F, et al. Coste económico del autotrasplante de progenitores hematopoyéticos. Med Clin (Barc) 1996;106:329-32.
9. Manasanch L, Carreras E, Monserrat E. Coste económico del trasplante autólogo de progenitores hematopoyéticos. Med Clin (Barc) 1997;108:558.
10. Vicent MG, Madero L, Chamorro L, Madero R, Díaz MA. Comparative cost analysis of autologous peripheral blood progenitor cell and bone marrow transplantation in pediatric patients with malignancies. Haematologica 2001;86:1087-94.
11. Lemoli RM, Bandini G, Leopardi G, Rosti G, Bonini A, Fortuna A, et al. Allogeneic peripheral blood stem cell transplantation in patients with early-phase hematological malignancy: a retrospective comparison of short-term outcome with bone marrow transplantation. Haematologica 1998;83:48-55.
12. Solano C, Martínez C, Brunet S, Tomás JF, Urbano-Ispizua A, Zuazu J, et al. Chronic graft-versus host disease after allogeneic peripheral blood or bone marrow transplantation from matched related donors: a case-control study. Bone Marrow Transplant 1998;22:1129-35.
13. Ustun C, Arslan O, Beksac M, Koc H, Gurman G, Ozcelik T, et al. A retrospective comparison of allogeneic peripheral blood stem cell and bone marrow trasnplantation. Results from a single center: a focus on the incidence of graft-vs-host disease and relapse. Biol Blood Marrow Transplant 1999;5:28-35.
14. Przepiorka D, Anderlini P, Saliba R, Clary K, Mehra R, Khouri I, et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 2001;98:1695-700.
15. Powles R, Mehta J, Kulkarni S, Treleaven J, Millar B, Marsden J, et al. Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomized trial. Lancet 2000;355:1231-7.
16. Faucher C, Fortanier C, Viens P, Le Corroller AG, Chabannon C, Camerlo J, et al. Clinical and economic comparison of lenograstim-primed blood cells (BC) and bone marrow (BM) allogeneic transplantation. Bone Marrow Transplant 1998;21(Suppl3):92-8.
17. Bennett CL, Waters TM, Stinson TJ, Almagor O, Pavletic ZS, Tarantolo SR, et al. Valuing clinical strategies early in development: a cost analysis of allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 1999;24:555-60.
18. Faucher C, Le Corroller AG, Biaise D, Novakovitch G, Manonni P, Moatti JP, et al. Comparison of G-CSF-primed peripheral blood progenitor cells and bone marrow auto transplantation: clinical assessment and cost-effectiveness. Bone Marrow Transplant 1994;14:895-901.
19. Uyl-de-Groot CA, Huijgens PC, Rutten FFH. Colony-stimulating factors and peripheral blood progenitor cell transplantation. Benefits and costs. Pharmacoeconomics 1996;10:23-35.
20. Tarella C, Castellino C, Locatelli F, Caracciolo D, Corradini P, Falda M, et al. G-CSF administration following peripheral blood progenitor cell (PBPC) autograft in lymphoid malignancies: evidence for clinical benefits and reduction of treatment costs. Bone Marrow Transplant 1998;21:401-7.